Ouabain promotes immune responses in WEHI-3 cells to generate leukemia mice through enhancing phagocytosis and natural killer cell activities in vivo.
Animals
Antineoplastic Agents, Phytogenic
/ therapeutic use
Cell Line, Tumor
Cytotoxicity, Immunologic
/ drug effects
Killer Cells, Natural
/ drug effects
Leukemia, Experimental
/ drug therapy
Lymphocyte Activation
/ drug effects
Mice
Mice, Inbred BALB C
Neoplasm Transplantation
Ouabain
/ therapeutic use
Phagocytosis
/ drug effects
immune response
macrophage
natural killer cell
ouabain
phagocytosis
Journal
Environmental toxicology
ISSN: 1522-7278
Titre abrégé: Environ Toxicol
Pays: United States
ID NLM: 100885357
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
05
12
2018
revised:
22
01
2019
accepted:
27
01
2019
pubmed:
15
2
2019
medline:
21
5
2019
entrez:
15
2
2019
Statut:
ppublish
Résumé
Ouabain, a cardiotonic steroid, was used for the treatment of heart failure and atrial fibrillation and induces cancer cell apoptosis in many human cancer cells including human leukemia cells. However, there are no reports to show the effects on immune responses in a leukemia mouse model. In this study, WEHI-3 cell generated leukemia mice were developed and treated by oral ouabain at 0, 0.75, 1.5, and 3 mg/kg for 15 days. Results indicated that ouabain did not affect body appearance, but decreased liver and spleen weights, B- and T-cell proliferation at all three doses treatment and increased CD19 cells at 3.0 mg/kg treatment, decreased CD3, CD11b, and Mac-3 cells levels compared with positive control. Furthermore, ouabain increased the macrophage phagocytosis from peripheral blood mononuclear cell and peritoneal cavity at all three doses treatment and increased NK cell activities. Ouabain restored GOT, GPT and LDH levels in WEHI-3 leukemia mice in vivo.
Substances chimiques
Antineoplastic Agents, Phytogenic
0
Ouabain
5ACL011P69
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
659-665Subventions
Organisme : Experiments and data analysis were performed in part through the use of the Medical Research Core Facilities Center, Office of Research and Development at China Medical University, Taichung, Taiwan
Organisme : Shin Kong Wu Ho-Su Memorial Hospital
ID : SKH-8302-104-NDR-12
Organisme : Cheng Hsin General Hospital
ID : 104-38
Informations de copyright
© 2019 Wiley Periodicals, Inc.